Earlier stages of cancer: is there scientific rationale for targeting the immune system? – Bristol-Myers Squibb sponsored session

Start: 08 Nov 2021, 14:45
End: 08 Nov 2021, 15:30

The complex, dynamic interplay between the immune system and cancer has been an area of intense research focus, ultimately leading to advances in the field of immuno-oncology. There is mechanistic rationale to evaluate immunotherapy in earlier stages of disease and using immune-based therapies earlier in a patient’s treatment
cycle is under evaluation in various tumour types with a view to improving clinical outcomes. Challenges involved in the development of new treatment approaches for early-stage cancers include improving our understanding of the tumour
microenvironment, the selection of patients at high risk of disease progression and considerations related to the sequencing and potential efficacy of later-line therapies.
At this symposium, Professor Jeff Evans (University of Glasgow) will review the rationale for targeting the immune system in earlier stages cancer and explore important research considerations within this field. We hope you will join us for this informative event.

This is a non-promotional webinar organised and funded by Bristol Myers Squibb intended for UK healthcare professionals and scientific researchers with an interest in Oncology.